Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rotavirus Vaccine Phase III Trials May Require 60,000 - 100,000 Patients

Executive Summary

Rotavirus vaccine Phase III studies may require between 60,000 and 100,000 patients to address rare adverse event risks, Thomas Fleming, PhD, University of Washington, said during the Vaccines & Related Biological Products Advisory Committee meeting May 11.

You may also be interested in...



Merck HPV Vaccine BLA Filing Expected In 2005, Four Years Before GSK

Merck's quadrivalent human papilloma virus vaccine could be approved by FDA up to four years before GlaxoSmithKline's HPV vaccine Cervarix is cleared for marketing in the U.S

Merck HPV Vaccine BLA Filing Expected In 2005, Four Years Before GSK

Merck's quadrivalent human papilloma virus vaccine could be approved by FDA up to four years before GlaxoSmithKline's HPV vaccine Cervarix is cleared for marketing in the U.S

Rotavirus Vaccine Workshop May Address Intussusception Biomarker Data

A potential rotavirus vaccine-related intussusception biomarker could be a topic at a September workshop organized by the Centers for Disease Control & Prevention's National Vaccine Program Office and the National Vaccine Advisory Committee.

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel